Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, December 13, 2017
Eisai's Aricept Approved for Additional Indication of Severe Alzheimer's Disease in China
Friday, December 8, 2017
Eisai: Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Combination Regimen
Wednesday, December 6, 2017
Eisai Submits Application for Expanded Indication Covering Hepatocellular Carcinoma for Anticancer Agent Lenvima in Taiwan
Thursday, November 30, 2017
Eisai's Resubmitted NDA for Anticancer Agent Halaven Accepted in China
Friday, November 24, 2017
Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting
Monday, November 20, 2017
Eisai Receives IT Business Award for Medication Administration Support Device e-OKUSURI-SAN
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December
Monday, November 6, 2017
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease
Tuesday, October 31, 2017
Eisai's New Drug Application of Anticancer Agent Lenvatinib for Hepatocellular Carcinoma Accepted in China
Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer's Diesase

Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: